Stockscreener 앱 받기
14.91
1.39%
-0.21
전일 마감가:
$15.12
열려 있는:
$15.12
하루 거래량:
476.89K
Relative Volume:
0.38
시가총액:
$753.65M
수익:
-
순이익/손실:
$-156.39M
주가수익비율:
-4.0407
EPS:
-3.69
순현금흐름:
$-123.06M
1주 성능:
+0.07%
1개월 성능:
-0.20%
6개월 성능:
+18.43%
1년 성능:
+56.45%
1일 변동 폭
$14.81
$15.42
1주일 범위
$14.41
$15.70
52주 변동 폭
$9.235
$19.00
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
명칭
Kalvista Pharmaceuticals Inc
전화
(857) 999-0075
주소
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Compare KALV vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
14.91 | 764.26M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 재확인 | Needham | Buy |
| 2026-01-06 | 재확인 | Needham | Buy |
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-12-18 | 개시 | BofA Securities | Buy |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2019-07-29 | 개시 | SVB Leerink | Outperform |
| 2019-03-20 | 개시 | Needham | Buy |
| 2018-10-30 | 개시 | Jefferies | Buy |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 개시 | BTIG Research | Buy |
모두보기
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
Benjamin Palleiko Sells 3,354 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock - MarketBeat
Will KalVista Pharmaceuticals Inc. stock benefit from automationJuly 2025 Retail & Weekly High Return Forecasts - mfd.ru
KalVista Pharmaceuticals (KALV) Stock Analysis: Unpacking A 123% Potential Upside - DirectorsTalk Interviews
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of All - pharmiweb.com
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - BioSpace
Travel Stocks: Should I hold or sell KalVista Pharmaceuticals Inc nowM&A Rumor & Technical Confirmation Alerts - baoquankhu1.vn
KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion (KALV) - Seeking Alpha
Is KalVista Pharmaceuticals Inc. a turnaround storyMarket Risk Report & Momentum Based Trading Signals - mfd.ru
Hereditary Angioedema Market to Surpass USD 3 Billion Baseline in 2023, Set for Robust Growth Through 2034 Across 7MM with 7,000 Diagnosed US Cases | DelveInsight - Barchart.com
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Market Catalysts: Does Global Blue Group Holding AG Equity Warrant have a sustainable dividendTrend Reversal & Safe Capital Preservation Plans - baoquankhu1.vn
KalVista Pharmaceuticals sees $1.5m stock purchase by Venrock - MSN
Responsive Playbooks and the KALV Inflection - Stock Traders Daily
Aug Sentiment: Is KalVista Pharmaceuticals Inc subject to activist investor interestPortfolio Value Report & Expert-Curated Trade Recommendations - baoquankhu1.vn
TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results - Yahoo Finance
Wall Street Analysts Believe KalVista Pharmaceuticals (KALV) Could Rally 116.4%: Here's is How to Trade - Yahoo Finance
KalVista Pharmaceuticals (KALV) Stock Analysis: Uncovering a 112% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Is KalVista Pharmaceuticals Inc forming higher highs and higher lowsJuly 2025 Recap & Safe Capital Growth Tips - baoquankhu1.vn
Quarterly Earnings: Is Intelligent Living Application Group Inc stock overvalued or fairly pricedAnalyst Downgrade & High Accuracy Swing Trade Signals - baoquankhu1.vn
What is KalVista Pharmaceuticals Incs P E ratio telling usMarket Risk Report & Technical Confirmation Alerts - baoquankhu1.vn
Bank of America Securities Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV) - The Globe and Mail
KalVista’s Pediatric HAE Trial for Sebetralstat Reaches Completion, Setting Up a Key Catalyst for KALV - TipRanks
Does KalVista Pharmaceuticals (KALV) have the potential to rally 117.98% as Wall Street analysts expect? - MSN
Understanding the Setup: (KALV) and Scalable Risk - Stock Traders Daily
Emerald Mutual Fund Advisers Trust Grows Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Emerald Advisers LLC Grows Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Hereditary Angioedema Market Poised for Strong Growth, Valued - openPR.com
Hereditary Angioedema Market Poised for Strong Growth, Valued at ~USD 3 Billion in 2023 and Set to Expand Through 2034: DelveInsight - Barchart.com
Multicare and KalVista collaboration in Latin America - The Pharma Letter
Multicare, KalVista to expand oral HAE treatment in Latin America - Mexico Business News
Aug Macro: What analysts say about KalVista Pharmaceuticals Inc stockQuarterly Market Review & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Recap Report: What chart patterns are forming on KalVista Pharmaceuticals IncWeekly Profit Recap & Detailed Earnings Play Strategies - baoquankhu1.vn
Can KalVista Pharmaceuticals Inc withstand a market correction2025 Sector Review & Breakout Confirmation Alerts - baoquankhu1.vn
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2026-01-16 10:42:21 - baoquankhu1.vn
Aug Weekly: Can Zoetis Inc sustain its profitabilityOptions Play & Technical Entry and Exit Tips - baoquankhu1.vn
Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect? - sharewise.com
Can KalVista Pharmaceuticals Inc stock sustain revenue growthQuarterly Earnings Report & Long-Term Growth Plans - Bộ Nội Vụ
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 7.2%Time to Sell? - MarketBeat
KalVista reports $49M in 2025 Ekterly revenue, shares rise - MSN
HAE treatment Ekterly hits $49M sales in months since July launch - Angioedema News
The Technical Signals Behind (KALV) That Institutions Follow - Stock Traders Daily
Analysts Expect Breakeven For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Before Long - 富途资讯
What is HC Wainwright's Forecast for KALV FY2030 Earnings? - MarketBeat
Health Check: How Prudently Does KalVista Pharmaceuticals (NASDAQ:KALV) Use Debt? - simplywall.st
Kalvista Stock Surges On Strong EKTERLY Uptake - Nasdaq
KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 52-Week High Following Analyst Upgrade - MarketBeat
KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug - Benzinga
Kalvista stock surges as Stifel reiterates Buy on strong Ekterly sales By Investing.com - Investing.com South Africa
Kalvista stock surges as Stifel reiterates Buy on strong Ekterly sales - Investing.com Nigeria
Kalvista Pharmaceuticals Inc (KALV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kalvista Pharmaceuticals Inc 주식 (KALV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Dec 08 '25 |
Sale |
16.51 |
7,294 |
120,424 |
424,520 |
| Sweeny Nicole | Chief Commercial Officer |
Nov 24 '25 |
Sale |
13.45 |
3,813 |
51,289 |
39,728 |
| Piekos Brian | Chief Financial Officer |
Nov 24 '25 |
Sale |
13.45 |
4,471 |
60,139 |
10,529 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Nov 24 '25 |
Sale |
13.45 |
4,331 |
58,256 |
223,508 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Nov 24 '25 |
Sale |
13.45 |
5,296 |
71,236 |
131,831 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Nov 24 '25 |
Sale |
13.45 |
10,940 |
147,154 |
416,189 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Nov 20 '25 |
Option Exercise |
0.00 |
87,390 |
376 |
220,964 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Nov 18 '25 |
Sale |
14.48 |
4,466 |
64,665 |
403,879 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Nov 18 '25 |
Sale |
14.48 |
2,683 |
38,848 |
133,574 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Nov 18 '25 |
Sale |
14.48 |
3,075 |
44,524 |
125,877 |
1.12%
0.87%
자본화:
|
볼륨(24시간):